A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess The Efficacy, Safety, And Tolerability Of PF-03715455 Administered Twice Daily By Inhalation For 12 Weeks In Subjects With Persistent Moderate To Severe Asthma Who Remain Uncontrolled Despite Treatment With Inhaled Corticosteroids (ICS) And Long-Acting Beta2 Agonists (LABA)
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs PF 3715455 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pfizer
- 13 Oct 2015 According to ClinicalTrials.gov, this study was terminated because of business reasons. No safety or efficacy concerns contributed to the termination of the study.
- 25 Sep 2015 Status changed from completed to discontinued as per ClinicalTrials.gov.
- 31 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.